Healthcare / Drug Manufacturers - Specialty & GenericMCE
$7.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 10%
FCF escenarios
weak_data · normalized FCF $-2.7M · quality 20.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$59M
P/E
19.4x
↓EV/EBITDA
7.4x
↓ROE
50.5%
↑Gross Margin
61.1%
↑Debt/Equity
7.21
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.1%
FCF CAGR
—
FCF margin
-3.6%
FCF / Net income
-1.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $75.2M · net income $2.6M · FCF $-2.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $75.2M | $75.2M | $66.3M | $58.5M | $57.8M |
| Net Income | $2.6M | $2.6M | $253449.61 | $-4.4M | $-8.9M |
| EBITDA | $10.9M | $10.9M | $9.1M | $3.1M | $-894289.82 |
| EPS | 0.36 | 0.36 | 0.03 | -0.60 | -1.21 |
| Gross Margin | 61.1% | 61.1% | 61.8% | 58.7% | 56.4% |
| Operating Margin | 9.7% | 9.7% | 7.7% | -3.2% | -4.1% |
| Net Margin | 3.4% | 3.4% | 0.4% | -7.6% | -15.5% |
| Balance Sheet | |||||
| Debt/Equity | 7.21 | 7.21 | 12.34 | 11.65 | 5.43 |
| Current Ratio | 1.42 | 1.42 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.7M | $-2.7M | $4.1M | $-4.7M | $-774370.55 |
| Returns | |||||
| ROE | 50.5% | 50.5% | 8.8% | -123.5% | -127.1% |
| Valuation | |||||
| P/E | 19.44 | 19.44 | 85.96 | — | — |
| EV/EBITDA | 7.42 | 7.42 | 5.57 | 15.29 | — |
| P/B | 9.87 | 9.87 | 7.59 | 2.45 | 3.31 |
| Growth & Yield | |||||
| Revenue Growth | 13.5% | 13.5% | 13.3% | 1.1% | — |
| EPS Growth | 941.1% | 941.1% | 105.7% | 50.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
20.1%
EPS terminal req.
$0.62
Spread vs growth
921.0%
5Y implied EPS CAGR
16.0%
EPS terminal req.
$0.75
Spread vs growth
925.2%
10Y implied EPS CAGR
12.9%
EPS terminal req.
$1.21
Spread vs growth
928.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+99.4%
Start / end P/E
100.5x → 19.2x
EPS bridge
0.03 → 0.36
Residual
-760.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.